
Please try another search
Aridis Pharmaceuticals, Inc. (Nasdaq: NASDAQ:ARDS), a biopharmaceutical company, today announced that it has entered into a definitive agreement for the issuance and sale of an aggregate of 6,000,000...
Aridis Pharmaceuticals, Inc. (Nasdaq: NASDAQ:ARDS) today announced preliminary top-line results from the randomized, double blinded, placebo-controlled Phase 2a study of AR-501, which evaluated the...
Aridis Pharmaceuticals Inc (NASDAQ: ARDS) announced preliminary topline results from the Phase 2a study of AR-501 in cystic fibrosis (CF) patients with confirmed Pseudomonas aeruginosa bacterial and...
MIAMI, FL, March 02, 2023 (GLOBE NEWSWIRE) -- Veru Inc. (NASDAQ:VERU), a biopharmaceutical company focused on developing novel medicines for COVID-19 and other viral ARDS-related diseases and for...
Investing.com - Aridis Pharma reported on Monday third quarter earnings that missed analysts' forecasts and revenue that fell short of expectations. Aridis Pharma announced earnings per share of...
By Sam Boughedda Investing.com — Aridis Pharmaceuticals Inc 's (NASDAQ:ARDS) monoclonal antibody cocktail treatment is potentially first-in-class, H.C. Wainwright analyst Vernon Bernardino told...
By Sam Boughedda Investing.com — Aridis Pharmaceuticals Inc (NASDAQ:ARDS) shares have rallied Tuesday morning. The rise is a result of news that the company's antibody cocktail AR-701 is effective...
Jan 2 (Reuters) - Aridis Pharmaceuticals Inc ARDS.O : * ARIDIS PHARMACEUTICALS INC - ANNOUNCED APPOINTMENT OF MICHAEL NAZAK AS CFO EFFECTIVE JANUARY 1, 2020 * ARIDIS PHARMACEUTICALS INC - NAZAK...
Are you sure you want to block %USER_NAME%?
By doing so, you and %USER_NAME% will not be able to see any of each other's Investing.com's posts.
%USER_NAME% was successfully added to your Block List
Since you’ve just unblocked this person, you must wait 48 hours before renewing the block.
I feel that this comment is:
Thank You!
Your report has been sent to our moderators for review